CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2016.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the first quarter, we reached significant milestones that have clarified our path to commercialization and increased the likelihood of approval for the Neuro-Spinal Scaffold™ for acute thoracic spinal cord injury. We established a measure of success for the INSPIRE study when we received approval for an amendment that defined the Objective Performance Criterion (OPC) as 25% or more of the patients in the study demonstrating an improvement of at least one ASIA Impairment Scale (AIS) grade by six months post-implantation.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the first quarter, we reached significant milestones that have clarified our path to commercialization and increased the likelihood of approval for the Neuro-Spinal Scaffold™ for acute thoracic spinal cord injury. We established a measure of success for the INSPIRE study when we received approval for an amendment that defined the Objective Performance Criterion (OPC) as 25% or more of the patients in the study demonstrating an improvement of at least one ASIA Impairment Scale (AIS) grade by six months post-implantation.
